Articles By Rob Wright, Chief Editor
What Would You Do?10/22/2020
A call with a young reader reveals a biopharmaceutical industry mentorship opportunity beyond science.
Will The Pandemic Be The Actual Death Of Print?10/1/2020
For years we’ve been hearing that “print” is dead. Despite the statistics, I still don’t believe this pandemic — or anything else — is going to eradicate publications printed on paper.
David Lucchino’s Circuitous Route To CEO Of Frequency Therapeutics10/1/2020
Biopharma CEO wasn’t David Lucchino’s first, second, or even third choice as a career path. Today, though, he uses elements of his diverse background to lead his second pharma startup, Frequency Therapeutics.
What Does Travel Look Like For You In 2021?9/24/2020
With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.
From Diligence To Execution — Tim Wright’s Approach To Leading MiMedx9/1/2020
Tim Wright shares his due diligence approach regarding MiMedx before becoming its CEO in 2019, along with how he went about implementing his 90-day business plan that would transform the company.
What Can A Conversation On Cars Reveal About A Leader?9/1/2020
How many CEOs of publicly traded companies do you think can claim to driving the exact same car that they did when they first got their start? Tim Wright can.
From Food To Pharma — Andrea Pfeifer’s Trek To Cure Alzheimer’s8/3/2020
CEO Andrea Pfeifer talks about why, years ago, she was convinced it was time to leave her career in the food industry and cofound AC Immune, a biopharma focused on one of the most difficult areas — Alzheimer’s disease.
Leading Through Crisis8/3/2020
Rob Wright talks about why a virtual BIO presentation was one of the best biopharma industry educational sessions he’s ever attended.
It’s Time We Ready Americans For The COVID-19 Long Haul7/15/2020
Rob Wright issues a call to action to everyone connected to the biopharmaceutical industry, recommending they begin communicating the realities of developing and distributing a COVID-19 vaccine by the end of this year.